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BRIEF REPORT
Reduction in Serum Aquaporin-4 Antibody Titers During
Development of a Tumor-Like Brain Lesion in a Patient With
Neuromyelitis Optica: A Serum AntibodyYConsuming Effect?
Fahmy Aboulenein-Djamshidian, MD, Romana Ho¨ftberger, MD, Patrick Waters, PhD,
Wolfgang Krampla, MD, Hans Lassmann, MD, Herbert Budka, MD, Angela Vincent, FRCPath,
and Wolfgang Kristoferitsch, MD
Abstract
Neuromyelitis optica (NMO) is an inﬂammatory demyelinating
disease of the CNS with severe involvement of the optic nerve and
spinal cord. Highly speciﬁc serum IgG autoantibodies (NMO-IgG)
that react with aquaporin-4 (AQP4), the most abundant CNS water
channel protein, are found in patients with NMO. However, in vivo
evidence combining the results of AQP4 antibody serum levels and
brain pathology is lacking. We report a patient with NMO whose
AQP4 antibody levels decreased simultaneously with clinical dete-
rioration caused by the development of a tumor-like brain lesion. In
the seminecrotic biopsied brain lesion, there was activated comple-
ment complex, whereas only very scattered immunoreactivity to
AQP4 protein was detectable. The decrease in serum AQP4 antibody
levels and the loss of AQP4 in the tumor-like lesion could represent a
‘‘serum antibodyYconsuming effect’’ during lesion formation.
Key Words: Aquaporin-4, Brain biopsy, Multiple sclerosis, Neuro-
myelitis optica, Serum level, Tumor-like lesion.
CASE REPORT
A 64-year-old female patient fulﬁlled all diagnostic criteria
for clinically deﬁnite neuromyelitis optica (NMO), including the
presence of serum NMO-IgG autoantibodies (1, 2). She had a history
of 3 episodes of longitudinally extensive (Q3 vertebral segments)
transversemyelitis in 2003, 2004, and 2005 (3Y5). Her exacerbations
were treated with high-dose intravenous methylprednisolone (ivMP)
for 5 days. Cerebrospinal ﬂuid analyses were performed twice in
2003 and 2004 and showed pleocytosis (22 and 44 cells/KL, respec-
tively), with activated lymphocytes, monocytes, neutrophils, and eosin-
ophils. Oligoclonal bands could not be detected in the cerebrospinal
ﬂuid (4Y6).
In 2005, the diagnosis was conﬁrmed by detection of NMO-
IgG through an indirect immunoﬂuorescence (IF) assay at the Mayo
Clinic Laboratories (Rochester, MN) (2). The test was obtained com-
mercially. Aquaporin-4 (AQP4) antibody (AQP4-ab) titers were assessed
with a ﬂuorescence-based immunoprecipitation assay during follow-up,
as described in detail (7). Long-term treatment with azathioprine and
oral prednisolone was initiated (4, 5). Oral prednisolone was tapered
and ﬁnally discontinued. Azathioprine dosing was adjusted to a lym-
phocyte count of 600 to 1,000 cells/KL.
In 2006, she had another exacerbation with optic neuritis (ON),
and the same therapeutic regimen was applied (ivMP treatment followed
by oral prednisolone, which was subsequently tapered and discontinued
in May 2006). Serum AQP4 titers from 2005 to 2007 and the clinical
course are shown in Figure 1 (left side of the graph, gray ﬁeld); these
have been included in previous reports (4Y6).
Aquaporin-4 antibody titers increased continuously during an
11-month period and reached a maximum shortly before new clinical
symptoms developed (December 2007 to March 2008). At this point,
ongoing immunosuppressive therapy with azathioprine had to be
switched to oral prednisolone because of elevated levels of liver
enzymes (Fig. 1, Day 1). At the same time AQP4-ab titers began to
decline. Brain magnetic resonance imaging (MRI) performed 3 weeks
later showed normal results (6). Approximately 4 weeks later, the
patient presented with agitation and prostration followed by progress-
ing difﬁculties with visual perception and orientation (Fig. 1, red ﬁeld).
On clinical examination approximately 6 weeks later, the patient
showed hemianopsia on the right; she was otherwise normal apart
from mild spastic paraparesis (sequela of 3 previous attacks of myeli-
tis). Neuropsychologic testing revealed major deﬁcits in visuospatial
and visuoperceptive abilities. The clinical manifestations were caused
by a large unique cystic seminecrotizing tumor-like brain lesion located
bioccipitally and in the corpus callosum (Fig. 2).
BRAIN BIOPSY
Three tissue cores from the stereotactic brain biopsy
included material from the center and the edge of the tumor-like
lesion. Two- to 4-Km-thick adjacent serial sections of parafﬁn
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sections were stained with hematoxylin and eosin, Luxol fast
blue, and Bielschowsky silver impregnation to assess inﬂam-
mation, demyelination, and axonal pathology, respectively.
Immunohistochemistry was carried out as previously described
(8). The well-characterized antibodies included monoclonal
(mouse) antibodies to CD3, CD4, CD8, CD20, CD79a, HLA-D,
and phosphorylated neuroﬁlament, and polyclonal (rabbit)
antibodies to C9neo (activated complement complex [9]), glial
ﬁbrillary acidic protein, AQP4 water channel protein, and
myelin basic protein. Immunohistochemistry and IF studies
of the patient’s serum taken 2 hours before the brain biopsy
were performed on the biopsy material of the patient’s tumor-
like lesion and on normal brain, gastric, and kidney tissues.
Established and modiﬁed protocols for immunohistochemistry
and IF were performed on 2- to 4-Km-thick parafﬁn sections,
as previously described (2, 10). Fluorescein isothiocyanateY
conjugated rabbit anti-human IgGAM was used as secondary
antibody. For confocal laser microscopy, essentially the same
laser scanning microscope and settings were used as previously
described in detail (8, 10). Results of routine histology, immu-
nohistochemistry, and IF studies are shown in Figure 3.
A ﬁrst follow-up brain MRI was performed 11 days after
the brain biopsy and 6 days after a course of ivMP (Fig. 1).
Marked reductions of lesion size and gadolinium enhance-
ment were found (data not shown). In a second follow-up
FIGURE 1. AntiYAQP4-ab titers and clinical course. Black circles,
AQP4-ab serum levels; black arrows, ON and brain MRI scans;
gray arrow, brain biopsy; black rectangle, therapy with azathio-
prine; Day 1, day when azathioprine was discontinued because
of elevated liver enzymes and therapy was switched to oral pred-
nisolone; asterisks, 5-day course of ivMP 1 g/day (i.e. after ON and
after brain biopsy); dashed line, therapy with low-dose predniso-
lone; dotted line, start of ongoing therapy with rituximab. The
previous disease course and AQP4-ab titers were presented in
detail elsewhere (3). The development of the large cystic NMO
tumor-like lesion took several weeks to become evident on
neuroimaging (red field).
FIGURE 2. Tumor-like lesion in NMO. Axial and sagittal planes show the large extension of the tumor-like NMO lesion. First row,
axial planes and T2-weighted MRI images; second row, axial planes and T1-weighted images with gadolinium; third row, sagittal
planes and fluid-attenuated inversion recovery sequence.
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MRI 5 weeks after the biopsy, the lesion showed a further
decrease in size (data not shown).
Our data support a crucial role for AQP4-ab/NMO-IgG
autoantibodies in the pathogenesis of NMO (2, 7, 11). As in
other patients with NMO, the tumor-like lesion in our patient
developed at sites of high AQP4 expression (12). Aquaporin-4
antibodies have been shown to bind to AQP4 water channel
protein on astrocyte foot processes, mainly at the blood-brain
barrier. These antibodies are predominantly of the IgG1 subtype
and are capable of activating complement (13). Their tar-
gets may be destroyed by activation of the lytic complement
complex or by opsonization (13). Within the center of the
FIGURE 3. Neuropathology of the tumor-like NMO lesion on brain biopsy and immunoreactivity of the patient’s serum to AQP4.
(A) Hematoxylin and eosin stain of the brain biopsy shows an inflammatory demyelinating lesion characterized by numerous
macrophages, inflammatory infiltrates composed of neutrophilic and eosinophilic granulocytes (arrows), and lymphocytes. (B) Luxol
fast blueYperiodic acid Schiff stain shows active demyelination. (C) Immunohistochemistry for SMI31 shows that axons are relatively
preserved within the lesion; arrow indicates an axonal spheroid. (D) Immunohistochemistry for glial fibrillary acidic protein reveals that
there is widespread loss of glial fibrillary acidic protein in the lesion center (asterisk); astrocytes were well preserved (but activated) at the
lesion border (arrow). (E) Immunohistochemistry with rabbit antiYAQP4-ab shows that AQP4 is markedly reduced in the NMO lesion.
The very small AQP4 residual immunoreactivity is confined only to astrocytes and to the glia limitans perivascularis (arrows). (FYI)Normal
parieto-occipital lobe tissue. Immunohistochemistry with rabbit antiYAQP4-ab shows intense staining for AQP4 in the cell bodies (arrow),
processes, and foot processes of astrocytes that compose the glia limitans perivascularis (F, arrowheads). (GYI) Confocal images show
labeling of rabbit antiYAQP4-ab (H, red) with the AQP4-abYpositive serum of the patient (I, green). Double labeling (G) shows
colocalization at the glia limitans perivascularis (arrows) of small capillaries and within cell bodies of astrocytes (arrowhead)
(yellow). Asterisk is within the capillary lumen. (J) Immunohistochemistry for activated complement complex (C3neo). Deposits
of terminal complement complex are found around vessels (arrows) in the NMO lesion. Original magnification: (A, B, E, F, J)
400; (C, D) 100; (GYI) 630.
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lesion in our patient, there was nearly complete AQP4 loss;
activated complement complex deposits and large numbers
of activated macrophages were found, as has been observed
previously on autopsy material by others (Fig. 3) (14Y16).
Eosinophils, CD4-positive lymphocytes, and plasma cells
within the lesions also emphasize the antibody-driven nature
of NMO. In a previous report, positive correlations between
AQP4-ab titers and length of spinal cord lesions, severity of
ON, or size of brain lesions were found (17). Our patient
showed very high titers of AQP4-ab despite ongoing immu-
nosuppressive therapy, whereas brain MRI performed before
her recent relapse yielded normal results (Fig. 1) (4, 5). The
increase in AQP4-ab titers before relapse corresponds to pre-
vious reports and occurred despite ongoing therapy with aza-
thioprine (4, 17). The peak AQP4-ab titer seems to coincide
with the initial development of the large tumor-like lesion
(Figs. 1, 2) (17). The steady subsequent decline (of more than
50%) in AQP4-ab titers, even before the onset of high-dose
steroid treatment (Fig. 1), is surprising and may indicate a
‘‘serum antibodyYconsuming effect’’ during lesion formation.
Consistent with previous ﬁndings, AQP4-ab titers con-
tinued to decrease after treatment with high-dose ivMP (4, 17).
Reduced gadolinium enhancement indicated restoration of
the blood-brain barrier 11 days after stereotactic brain biopsy
and 6 days after a course of high-dose ivMP. It is possible
that the low-dose prednisolone therapy contributed to the
decline of AQP4 titers, but previous immunosuppressive
therapy with azathioprine did not prevent the increase in
AQP4 titers before tumor-like lesion formation (4). Our data
are the ﬁrst to combine serum and biopsy analyses, which
lend further support to the potential role of AQP4-ab in the
pathogenesis of NMO.
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